Phospho thr389 p70s6k sc 11759

Manufactured by Santa Cruz Biotechnology

Phospho Thr389 P70S6K (sc-11759) is an antibody that detects the phosphorylated form of the p70 S6 kinase (P70S6K) protein at the Thr389 residue. P70S6K is a serine/threonine protein kinase that plays a key role in the regulation of protein synthesis and cell growth.

Automatically generated - may contain errors

Lab products found in correlation

Torin1 cay10997, by Cayman Chemical (2 mentions) Bafilomycin a1 b1793 2ug, by Merck Group (2 mentions) Total ulk1 antibody, by Cell Signaling Technology (2 mentions) Chloroquine c6628, by Merck Group (1 mentions) Beclin 1 antibody, by Cell Signaling Technology (1 mentions) Lc 3 antibody nb100 2220, by Novus Biologicals (1 mentions) Total s6 antibody, by Cell Signaling Technology (1 mentions) β tubulin, by Merck Group (1 mentions) β actin antibody, by Merck Group (1 mentions) Lc3 nb100 2220, by Novus Biologicals (1 mentions) Gsk2578215a, by Bio-Techne (1 mentions) Mjff2, by Abcam (1 mentions) Mli 2, by Bio-Techne (1 mentions) Lrrk2 in 1, by Bio-Techne (1 mentions) β actin, by Merck Group (1 mentions) P62 610833, by BD (1 mentions)

Close spelling variants of this product

Phospho-p70S6K P70S6K

2 protocols using phospho thr389 p70s6k sc 11759

Evaluation of LRRK2 and VPS34 Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

The LRRK2in1 compound and the VPS34in1 were purchased from the Division of Signal Transduction Therapy, School of Life Sciences, and University of Dundee, UK. The GSK2578215A compound was purchased from Tocris. Bafilomycin A1 (B1793-2UG), Chloroquine (C6628) and Wortmannin (W3144-250UL) were purchased from Sigma-Aldrich. Torin-1 (CAY10997) was purchased from Cayman Chemicals.
Antibodies used were as follows: LC3 antibody (NB100-2220, Novus Biologicals); LRRK2 antibodies (MJFF#2, 3514-1/ab133474, Epitomics); total S6 antibody (2317, Cell Signalling); phospho Ser235/236 S6 antibody (2211S, Cell Signalling); total P70S6K antibody (sc-8418, Santa Cruz); phospho Thr389 P70S6K (sc-11759, Santa Cruz); total ULK1 antibody (8054 and 4773, Cell Signalling); phospho Ser757 ULK1 antibody (6888, Cell Signalling); Beclin-1 antibody (3738, Cell Signalling); β-actin antibody (A1978, Sigma Aldrich); β-tubulin (T6199, Sigma Aldrich).

Manzoni C., Mamais A., Roosen D.A., Dihanich S., Soutar M.P., Plun-Favreau H., Bandopadhyay R., Hardy J., Tooze S.A., Cookson M.R, & Lewis P.A. (2016). mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1. Scientific Reports, 6, 35106.

+ Open protocol

+ Expand

LRRK2 inhibitor-mediated autophagy regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Chemical compounds were purchased as follows: LRRK2in1 [24 (link)] from the Division of Signal Transduction Therapy, School of Life Sciences, University of Dundee, U.K.; GSK2578215A and MLi-2 from Tocris [25 (link)]; bafilomycin-A1 (B1793-2UG) and cycloheximide (01810-1G) from Sigma-Aldrich; torin-1 (CAY10997) from Cayman Chemicals. Antibodies used were as follows: LC3 (NB100-2220, Novus Biologicals); total P70S6K (sc-8418, Santa Cruz); phospho Thr389 P70S6K (sc-11759, Santa Cruz); p62 (610833, BD Transduction Labs); total ULK1 antibody (8054 and 4773, Cell Signalling); phospho Ser757 ULK1 antibody (6888 and D7O6UCell Signalling); phospho Ser555 ULK1 antibody (5869, Cell Signalling); total LRRK2 antibody (MJFF2, Abcam); phosphor Ser935 LRRK2 antibody (UDD2, Abcam) and β-actin (A1978, Sigma-Aldrich). AMPK activator (A769662) was kindly provided by Dr MPMS.

Manzoni C., Mamais A., Dihanich S., Soutar M.P., Plun-Favreau H., Bandopadhyay R., Abeti R., Giunti P., Hardy J., R. Cookson M., Tooze S.A, & Lewis P.A. (2018). mTOR independent alteration in ULK1 Ser758 phosphorylation following chronic LRRK2 kinase inhibition. Bioscience Reports, 38(2), BSR20171669.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!